STOCK TITAN

Chimerix, Inc. - $CMRX STOCK NEWS

Welcome to our dedicated page for Chimerix news (Ticker: $CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chimerix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chimerix's position in the market.

Rhea-AI Summary
Chimerix (NASDAQ:CMRX) appoints Thomas Riga as Chief Operating and Commercial Officer, leveraging his 25 years of oncology commercialization and business development experience to advance ONC201 toward commercialization. Riga's previous leadership roles at Spectrum Pharmaceuticals, Dendreon, Amgen, and Eli Lilly and Company, coupled with his B.S. in Biology and Chemistry, position him to drive Chimerix's growth and bring potentially life-altering drugs to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
management
-
Rhea-AI Summary
Chimerix, a biopharmaceutical company, reported financial results for Q3 2023 and provided an operational update. The Phase 3 ACTION study for ONC201 is ongoing with 113 sites activated across 12 countries. Interim survival and PFS data are on track to report in 2025. The company is actively recruiting for ONC206 dose escalation studies, with enrollment on track to complete in the first half of 2024. Chimerix reported a net loss of $24.0 million for Q3 2023. Research and development expenses increased to $17.4 million, while general and administrative expenses increased to $9.3 million. The company expects to end the year with over $200 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
-
Rhea-AI Summary
Chimerix to host conference call and webcast to report Q3 2023 financial results and provide business overview
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Chimerix to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences
-
Rhea-AI Summary
Chimerix announced the publication of data supporting ONC201 as a treatment for H3 K27M-mutant diffuse midline gliomas. Patients treated with ONC201 showed a median overall survival of 21.7 months compared to 12 months in historical controls. The treatment disrupts key metabolic and epigenetic pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary
Chimerix (CMRX) is conducting a Phase 3 ACTION study across 11 countries with 77 sites activated, expecting the first interim overall survival analysis in early 2025. They also anticipate completing ONC206 dose escalation in the first half of 2024 with $233 million available for operations as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
Rhea-AI Summary
Chimerix (NASDAQ:CMRX) to Report Q2 2023 Financial Results and Business Overview on August 3, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
conferences
Chimerix, Inc.

Nasdaq:CMRX

CMRX Rankings

CMRX Stock Data

86.99M
74.39M
1.34%
50.01%
1.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DURHAM

About CMRX

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed